



This is an abridged prospectus containing salient features of the Red Herring Prospectus dated October 30, 2025 (the “RHP”). You are encouraged to read greater details available in the RHP (Download link: <https://curisls.com>) Unless otherwise specified all capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

THIS ABRIDGED PROSPECTUS CONSISTS OF 8 (EIGHT) PAGES. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.


CURIS LIFESCIENCES LIMITED

CIN: U24230GJ2016PLC086559 **Date of Incorporation:** March 23, 2016

Registered Office	Contact Person	Email and Telephone	Website
PF-23, GIDC Sanand - II, Industrial Estate, Ahmedabad, Sanand, Gujarat-382110, India	Mr. Nikhil Purohit; Company Secretary and Compliance Officer	Tel No: +91 99045 22543 Email Id: cs@curisls.com	https://curisls.com

PROMOTERS OF OUR COMPANY: MR. DHARMESH DASHARATHBHAI PATEL, MR. SIDDHANT JAYANTIBHAI PAWASIA, MR. PIYUSH GORDHANBHAI ANTALA AND MR. JAIMEK MANSUKHLAL PATEL

DETAILS OF THE ISSUE

Type of Issue (Fresh/OFS/Fresh & OFS)	Fresh Issue Size (In ₹ Lakhs)	OFS Size (by no. of shares or by amount in Rs)	Total Issue Size (In ₹ Lakhs)	Issue Under 229(1)/229(2)	Share Reservation			
					Qualified Institutional Bidder	Non Institutional Investor	Individual Investor	Market Maker
Fresh Issue	21,50,000 Equity Shares of face value of ₹ 10 each (“Equity Shares”) aggregating up to ₹ [●] lakhs (“Issue”)	Nil	21,50,000 Equity Shares of face value of ₹ 10 each (“Equity Shares”) aggregating up to ₹ [●] lakhs (“Issue”)	The Issue Is Being Made Pursuant To Regulation 229(1) Of Chapter IX Of Sebi IcdR Regulations, 2018. As The Company’s Post Issue Paid-Up Capital Is Less Than ₹ 1000 Lakhs.	Not more than 10,18,000 Equity Shares.	Not less than 3,08,000 Equity Shares.	Not less than 7,16,000 Equity Shares.	Not less than 1,08,000 Equity share.

These equity shares are proposed to be listed on Emerge Platform of National Stock Exchange of India Limited.

DETAILS OF OFFER FOR SALE, SELLING SHAREHOLDERS AND THEIR AVERAGE COST OF ACQUISITION – NOT APPLICABLE AS THIS IS A FRESH ISSUE OF EQUITY SHARES	
ELIGIBILITY FOR THE ISSUE	
Whether the company is compulsorily required to allot at least 75% of the net offer to public, to qualified institutional buyers - No	
Price Band, Minimum Bid Lot & Indicative Timelines	
Price Band*	Rs. 120/- to Rs. 128/- Per Equity Share of face value of Rs. 10/- each.
Minimum Bid Lot Size	For details of minimum bid lot size, please refer to price band advertisement published in two national daily newspapers (one each in English and in Hindi) with wide circulation and one daily regional newspaper with wide circulation at least two working days prior to the Bid / Issue Opening Date.
Anchor Portion Issue Opens/Closes On**	Thursday, November 06, 2025
Bid/Issue Opening Date	Friday, November 07, 2025
Bid/Issue Closing Date	Tuesday, November 11, 2025
Finalization of Basis of Allotment with the Designated Stock Exchange	On or before Wednesday, November 12, 2025
Initiation of Allotment / Refunds / Unblocking of Funds from ASBA Account or UPI ID linked bank account	On or before Thursday, November 13, 2025
Credit of Equity Shares to Demat accounts of Allottees	On or before Thursday, November 13, 2025
Commencement of trading of the Equity Shares on the Stock Exchange	On or before Friday, November 14, 2025

*For details of price band and Basis for Issue Price, please refer to price band advertisement and the chapter titled “Basis for Issue Price” on page 109 of the RHP.

**Our Company, in consultation with the BRLM, consider participation by Anchor Investors in accordance with the SEBI (ICDR) Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/Issue Opening Date i.e. Thursday, November 06, 2025.

The Weighted average cost of acquisition of all Equity Shares transacted over the trailing eighteen months from the date of RHP

Period	Weighted Average Cost of Acquisition (in Rs.)	Upper end of the Price Band (Rs. 128) is ‘X’ times the weighted Average cost of Acquisition	Range of acquisition price: Lowest Price – Highest Price (in Rs.)
--------	---	---	---

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

Trailing eighteen months from the date of RHP	Nil	NA	NA
---	-----	----	----

WACA: Weighted Average Cost of Acquisition shall be calculated on fully diluted basis for the trailing eighteen months from the date of RHP.

RISKS IN RELATION TO THE FIRST ISSUE
The face value of the Equity Shares is ₹ 10/- each. The Floor Price, the Cap Price and the Issue Price to be determined by our Company in consultation with the BRLM on the basis of the assessment of market demand for our Equity Shares by way of the Book Building Process, as disclosed in “ Basis for Issue Price ” beginning on page 109 or in case where, Price Band is not disclosed otherwise, will be advertised in two national daily newspapers (one each in English and in Hindi) with wide circulation and one daily Gujarati regional newspaper with wide circulation at least two working days prior to the Bid / Issue Opening Date, should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.
GENERAL RISK
Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in this Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of this Red Herring Prospectus. Specific attention of the investors is invited to chapter titled “ Risk Factors ” beginning on page 25 of the Red Herring Prospectus and on page 8 of this Abridged Prospectus.
PROCEDURE
You may obtain a physical copy of the Bid-cum-Application Form and the RHP from the stock exchange, syndicate members, registrar to the issue, share transfer agents, depository participants, stock brokers, underwriters, bankers to the issue, investors’ associations or Self Certified Syndicate Banks.
If you wish to know about processes and procedures applicable to this issue, you may request for a copy of the RHP and/or the General Information Document (GID) from the BRLM’s or download it from the website of the Stock Exchange i.e. www.nseindia.com and the BRLM at www.finaaxcapital.com
PRICE INFORMATION OF BRLM
This being the first issue managed by the Book Running Lead Manager, the stated disclosure is not applicable.

Name of Book Running Lead Manager and contact details (telephone and email id) of BRLM	FINAAX CAPITAL ADVISORS PRIVATE LIMITED Address: B-401, The First, B/s Keshavbaug Party Plot, I I M, Ahmedabad-380015, Gujarat, India. Email Id: info@finaaxcapital.com Investors Grievance Id: investors@finaaxcapital.com Contact Person: Mr. Ikshit Shah/Mr. Yash Doshi Telephone Number: +91 94295 50695 / 95375 94321 Website: www.finaaxcapital.com SEBI Registration Number: INM000013244 CIN: U64990GJ2023PTC147118
Name of Syndicate Member	Swastika Investmart Limited
Name of Market Maker	RS Wealth Management Private Limited
Name of Registrar to the Issue and contact details (telephone and email id)	MUFG INTIME INDIA PRIVATE LIMITED (Formerly Link Intime India Private Limited) Address: C- 101, 247 Park L B S Marg, Vikhroli West, Mumbai, Maharashtra- 400083 Tel No.: +91 810 811 4949 Email Id: curislifesciences.smeipo@in.mpms.mufg.com Investor Grievance Email: curislifesciences.smeipo@in.mpms.mufg.com Website: www.in.mpms.mufg.com Contact Person: Shanti Gopalkrishnan SEBI Registration No.: INR000004058 CIN: U67190MH1999PTC118368
Name of Statutory Auditor	M/S B. T. VORA & CO., CHARTERED ACCOUNTANTS
Name of Peer Reviewed Auditor	M/S S. N. SHAH & ASSOCIATES, CHARTERED ACCOUNTANTS
Name of Credit Rating Agency and the rating or grading obtained, if any	Not Applicable
Name of Debenture Trustee, if any	Not Applicable
Self-Certified Syndicate Banks	The list of banks is available on https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes
Non-Syndicate Registered Brokers	You can submit Bid cum Application Forms in the Issue to Non Syndicate Registered Brokers at the Non- Syndicate Broker Centres. For further details, see chapter titled “ Issue Procedure ” beginning on page 324 of the the RHP.
Details regarding website address(es)/ link(s) from which the investor can obtain list of registrar to issue and share transfer agents, depository participants and stock brokers who can accept application from investor (as applicable)	https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes

PROMOTERS OF THE ISSUER COMPANY			
Sr. No.	Name	Individual/ Corporate	Experience & Educational Qualification /Corporate Information
1	Dharmesh Dasharathbhai Patel	Individual	Mr. Dharmesh Dasharathbhai Patel, 51 years old, serves as the Chairman and Managing Director of our Company. He holds degree of Bachelor of Pharmacy from Saurashtra University, Rajkot and has more than 15 years of experience in the pharmaceutical industry. He has been associated with our Company since its inception. Previously, he was a partner at M/s. Loreto Pharmaceuticals and worked as a Senior Chemist (Powder Filling) at Trilokaa Parenterals Private Limited during the financial year 1997-1999. He is also partner at M/s. Macline Pharmaceuticals since 2015, providing expert opinions on marketing and new product development, and has been a partner at Biocare Formulations since 2011. Currently, he oversees financial and administration department of the Company.
2	Siddhant Jayantibhai Pawasia	Individual	Mr. Siddhant Jayantibhai Pawasia aged 40 years has been a Non-Executive Director of our Company since its incorporation. He completed his Secondary Education from Gujarat Secondary Education Board, Gandhinagar. He has an experience of more than 13 years in the field of Construction and Pharmaceutical Industry. He founded J D Buildcon, a sole proprietorship, where he oversees civil works and construction activities.
3	Piyush Gordhanbhai Antala	Individual	Mr. Piyush Gordhanbhai Antala, 41 years old, serves as the Whole-Time Director of our Company. He Holds degree of Bachelor of Pharmacy from Rajiv Gandhi University of Health Sciences, Karnataka and has more than 15 years of experience in the pharmaceutical industry. He has been associated with our Company since its inception. Prior to this, he worked with Lincoln Pharmaceuticals Limited during the financial year 2009-2010. He was a partner at M/s. Loreto Pharmaceuticals and has been a partner at Biocare Formulations since 2011. He also partnered with M/s. Macline Pharmaceuticals during the financial year 2015-19. Currently, he oversees the execution of all manufacturing operations within our Company.
4	Jaimik Mansukhbhai Patel	Individual	Mr. Jaimik Mansukhlal Patel, aged 39 years, serves as the Whole-time Director of our Company. He holds degree of Bachelor of Pharmacy from Rajiv Gandhi University of Health Sciences, Karnataka and degree of Master of Science with Commendation in Pharmacology from University of Hertfordshire, United Kingdom. He has been associated with our Company since its inception. He gained valuable experience in pharmaceutical medicine products while working in various Organisations. Subsequently, he was a partner in M/s. Medheal Pharmaceutical, a partnership firm, from financial year 2011 to 2016. With more than 13 years of experience in the pharmaceutical industry, he currently oversees legal and marketing department of the Company.

BUSINESS MODEL / BUSINESS OVERVIEW AND STRATEGY
<p>Curis Lifesciences is the pharma manufacturer, specializing in manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral Liquid, Sterile Ophthalmic Ointments. We operate in global as well as domestic markets. We undertake manufacturing activities on loan license, Contract Manufacturing and Direct Export basis/Own Brand Marketing basis. In terms of the nature of manufacturing and business activities, our business can be bifurcated in following 3 categories:</p> <p>1. Loan License manufacturing:</p> <p>Under this vertical, our company carry outs manufacturing under Loan License arrangement, where all raw materials and excipients are procured and delivered by the client. Further the client provides us with necessary supporting documents and formulations. On instructions of the client our company undertakes manufacturing activities under observation of a chemist, representing the customer. In summary, our company would perform manufacturing activities as a job work on behalf of the loan licensing company for the product. Our customers for loan license manufacturing activities are domestic.</p> <p>2. Contract Manufacturing:</p> <p>Under this vertical, our company carry outs manufacturing under Contract Manufacturing arrangement, where our Company would be responsible for procuring and handling all ingredients, raw materials, and packaging materials. Further, all necessary supporting documents and formulations required under manufacturing process would be procured / provided by our company. However, the client, is responsible for providing the brand name and product composition. Moreover, all marketing and distribution responsibilities rests with the client. Our customers for contract manufacturing activities can be further bifurcated under two major categories, as follows:</p> <p>a) Merchant Exporters b) Domestic Suppliers</p> <p>3. Direct Export/Own Brand Manufacturing:</p> <p>Under this vertical, our company manufactures products registered by itself in foreign country and sells the said products in foreign country through its distribution network. All ingredients, including raw materials and packaging materials, are purchased and handled by our company. Additionally, we are responsible for all marketing and distribution activities. The brand name and product composition is owned by us only. Currently, we are engaged in direct export under our own brands in two countries in the Republic of Yemen and Kenya.</p> <p><i>Further details, please see chapter titled “Business Overview” beginning on page 133 of the Red Herring Prospectus.</i></p> <p>Product/Service Offering: Our product portfolio includes Tablets, Capsules, External Preparation, Oral Liquid, and Sterile Ophthalmic Ointment.</p> <p><i>For further details, please see chapter titled “Business Overview” beginning on page 133 of the Red Herring Prospectus.</i></p> <p>Geographies Served: Our Company caters to domestic and international markets through Merchant Export and Direct Export.</p> <p><i>For further details, please see chapter titled “Business Overview” beginning on page 133 of the Red Herring Prospectus.</i></p> <p>Intellectual Property, if any: For details of Intellectual Property, please see chapter titled “Government and Other Approvals” beginning on page 292 of the Red Herring Prospectus.</p> <p>Market Share: Not ascertainable</p> <p>Manufacturing plant, if any: PF-23, GIDC Sanand - II, Industrial Estate, Ahmedabad, Sanand, Gujarat-382110, India</p> <p>Employee Strength: As of July 31, 2025, our company has 95 permanent employees at various levels of the Organization.</p>

Key Performance Indicators:

(₹ In lakhs except percentages and ratios)

Particulars	Period Ended on	For the year ended		
	July 31, 2025	March 31, 2025	March 31, 2024	March 31, 2023
Revenue from operations ⁽¹⁾	1,950.39	4,913.24	3,555.57	3,544.88
Revenue from operations – domestic (as % of total revenue from operation) ⁽²⁾	100.00%	99.97%	99.44%	99.00%
Revenue from operations – International (as % of total revenue from operation) ⁽³⁾	-	0.03%	0.56%	1.00%
EBITDA ⁽⁴⁾	423.56	953.73	838.76	327.59
EBITDA (%) Margin ⁽⁵⁾	21.72%	19.41%	23.59%	9.24%
PAT ⁽⁶⁾	287.16	610.51	486.70	187.53
PAT Margin ⁽⁷⁾	14.72%	12.43%	13.69%	5.29%
ROE (%) ⁽⁸⁾	16.26%	55.25%	141.51%	2752.56%
ROCE (%) ⁽⁹⁾	11.65%	27.83%	33.57%	14.83%
Current Ratio ⁽¹⁰⁾	1.57	1.78	1.21	0.94
Debt to Equity Ratio ⁽¹¹⁾	0.80	0.96	2.91	16.10
Inventory Turnover Ratio ⁽¹²⁾	0.22	2.32	2.85	4.67
Debt Service Coverage Ratio ⁽¹³⁾	14.00	5.68	7.28	2.36

Notes:

⁽¹⁾ Revenue from operation means revenue from sales

⁽²⁾ Operating revenue generated within the home country and is expressed as a percentage of the revenue from operations.

⁽³⁾ Operating revenue generated from foreign markets and is expressed as a percentage of revenue from operations.

⁽⁴⁾ EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses - Other Income

⁽⁵⁾ EBITDA Margin is calculated as EBITDA divided by Revenue from Operations;

⁽⁶⁾ PAT is calculated as Profit before tax – Taxes;

⁽⁷⁾ PAT Margin is calculated as PAT for the period/year divided by revenue from operations.

⁽⁸⁾ ROE is calculated as net profit after tax for the year / period divided by Average Shareholder Equity.

⁽⁹⁾ Return on Capital Employed (RoCE) is calculated as EBIT divided by capital employed, which is defined as shareholders' equity plus total borrowings [Current & Non – Current]

⁽¹⁰⁾ Current Ratio is calculated as Total Current Assets divided by Total Current Liabilities.

⁽¹¹⁾ Debt-Equity Ratio is calculated as Total Debt divided by Adjusted Net-Worth as per Restated Financial Statements.

⁽¹²⁾ Inventory Turnover Ratio is calculated as Cost of Goods Sold divided by Average Inventories

⁽¹³⁾ Debt Service Coverage Ratio is calculated as Earnings available for Debt Service divided by Interest payment plus Principal

BOARD OF DIRECTORS				
Sr. No.	Name	Designation (Independent/ Whole time/ Executive/ Nominee)	Experience & Educational Qualification	Other Directorships
1	Mr. Dharmesh Dasharathbhai Patel	Chairman and Managing Director	Mr. Dharmesh Dasharathbhai Patel, 51 years old, serves as the Chairman and Managing Director of our Company. He holds degree of Bachelor of Pharmacy from Saurashtra University, Rajkot and has more than 15 years of experience in the pharmaceutical industry. He has been associated with our Company since its inception. Previously, he was a partner at M/s. Loreto Pharmaceuticals and worked as a Senior Chemist (Powder Filling) at Trilokaa Parenterals Private Limited during the financial year 1997-1999. He is also partner at M/s. Macline Pharmaceuticals since 2015, providing expert opinions on marketing and new product development, and has been a partner at Biocare Formulations since 2011. Currently, he oversees financial and administration department of the Company.	Nil
2	Mr. Piyush Gordhanbhai Antala	Whole-Time Director	Mr. Piyush Gordhanbhai Antala, 41 years old, serves as the Whole-Time Director of our Company. He Holds degree of Bachelor of Pharmacy from Rajiv Gandhi University of Health Sciences, Karnataka and has more than 15 years of experience in the pharmaceutical industry. He has been associated with our Company since its inception. Prior to this, he worked with Lincoln Pharmaceuticals Limited during the financial year 2009-2010. He was a partner at M/s. Loreto Pharmaceuticals and has been a partner at Biocare Formulations since 2011. He also partnered with M/s. Macline Pharmaceuticals during the financial year 2015-19. Currently, he oversees the execution of all manufacturing operations within our Company.	Nil

3	Mr. Jaimik Mansukhlal Patel	Whole-Time Director	Mr. Jaimik Mansukhlal Patel, aged 39 years, serves as the Whole-time Director of our Company. He holds degree of Bachelor of Pharmacy from Rajiv Gandhi University of Health Sciences, Karnataka and degree of Master of Science with Commendation in Pharmacology from University of Hertfordshire, United Kingdom. He has been associated with our Company since its inception. He gained valuable experience in pharmaceutical medicine products while working in various Oranisations. Subsequently, he was a partner in M/s. Medheal Pharmaceutical, a partnership firm, from financial year 2011 to 2016. With more than 13 years of experience in the pharmaceutical industry, he currently oversees legal and marketing department of the Company.	Nil
4	Mr. Siddhant Jayantibhai Pawasia	Non-Executive Director	Mr. Siddhant Jayantibhai Pawasia aged 40 years has been a Non-Executive Director of our Company since its incorporation. He completed his Secondary Education from Gujarat Secondary Education Board, Gandhinagar. He has an experience of more than 13 years in the field of Construction and Pharmaceutical Industry. He founded J D Buildcon, a sole proprietorship, where he oversees civil works and construction activities.	Nil
5	Mr. Chand Rameshbhai Kanabar	Independent Director	Mr. Chand Rameshbhai Kanabar, aged 30 years, serves as an Independent Director of our Company. He holds degree of Bachelor of Commerce and degree of Master of Commerce from Saurashtra University, Rajkot. Mr. Chand has accumulated diverse professional experience, having worked as an Audit Assistant at V M Vithani & Co. from March 2013 to April 2016, followed by roles as Senior Executive - Finance & Accounts at Kunwarji Wealth Solutions from April 2016 to March 2018, and Vice President - Sales and Business Development at Shiv Investment from April 2018 to September 2020. Currently, he also serves as the Director at Accretion Pharmaceuticals Limited, Golden Sparrow Consultancy Private Limited and Riddhi Display Equipments Limited.	1. Accretion Pharmaceuticals Limited. 2. Riddhi Display Equipments Limited. 3. Golden Sparrow Consultancy Private Limited.
6	Ms. Grishma A Shewale	Independent Director	Ms. Grishma Ajay Shewale, aged 33 years, serves as an Independent Director of the Company. She holds degree of Bachelor of Commerce and Bachelor of Laws from The Maharaja Sayajirao University of Baroda and degree of Master of Commerce from Sardar Patel University, Vallabh Vidyanagar. She also holds a degree of Company Secretary from the Institute of Company Secretaries of India. With more than 5 years of experience in secretarial and corporate matters, Ms. Shewale has expertise as a Company Secretary and Compliance Officer, bringing valuable insights to her role as an Independent Director. Currently, she also serves as Company Secretary at I Secure Credit & Capital Services Limited.	1. Riddhi Display Equipments Limited. 2. Shining Tools Limited 3. Accretion Pharmaceuticals Limited.
7	Ms. Dhruvi Shyam Kapadia	Independent Director	Ms. Dhruvi Shyam Kapadia, aged 32, is an Independent Director of our Company. She holds degree of Bachelor of Commerce and Bachelor of Laws from Veer Narmad South Gujarat University, Surat and degree of Company Secretary from the Institute of Company Secretaries of India. She has more than 4 years of experience in the secretarial and compliance matters. She began her career as Company Secretary and Compliance Officer at Bindal Exports Limited (July 2020 – Feb 2022), then moved to Arham Wealth Management Private Limited (March 2022 – June 2023). She continued with 7NR Retail Limited (June 2023 – March 2024) and Sunrise Efficient Marketing Limited (April 2024 – Dec 2024). Currently, she serves as Company Secretary at Kansal Spinning Mills Private Limited.	1. Shining Tools Limited 2. Bhatia Colour Chem Limited 3. Mittal Sections Limited

For further details in relation to our Board of Directors, see chapter titled “**Our Management**” beginning on page 212 of the Red Herring Prospectus.

OBJECT OF THE ISSUE

Details of means of finance-

The fund requirements for each of the objects of the issue are stated as follows:

(₹ in lakhs)

Sr. No.	Object	Amount Required	From IPO Proceeds	Internal Accruals / Equity / Reserves / Balance from Long/Short Term Borrowing
1	Capital Expenditure towards Upgradation/Improvement of our existing Manufacturing Facilities	244.27	244.27	-
2	Capital Expenditure towards Construction of a Storage Facility	361.99	361.99	-
3	Pre-payment/Repayment of outstanding Secured Loans	186.45	186.45	-
4	Product Registrations in other countries	269.30	269.30	-
5	Funding our Working Capital Requirements	1,125.00	1,125.00	2,767.45
6	General Corporate Purposes [#]	●	●	●
	Net Issue Proceeds	●	●	●

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

For further details, see chapter titled “**Objects of the Issue**” beginning on page 91 of the Red Herring Prospectus.

#The amount utilized for general corporate purposes shall not exceed 15% or ₹ 1,000 Lakhs, whichever is lower of the Gross Proceeds of the Issue.

*To be determined upon finalisation of the Issue Price and updated in the Prospectus prior to filing with the RoC.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilization of issue proceeds of past public issues / rights issue, if any, of the Company in the preceding 10 years – Nil

Name of monitoring agency, if any – Not Applicable

Terms of Issuance of Convertible Security, if any - Not Applicable

Shareholding Pattern:

Sr. No.	Particulars	Pre Issue number of shares	% Holding of Pre issue
1	Promoter and Promoter Group	55,00,000	92.68
2	Public	4,34,434	7.32
	Total	59,34,434	100.00

Number/amount of equity shares proposed to be sold by selling shareholders. – Not Applicable

RESTATED AUDITED FINANCIALS

(₹ in Lakhs, as otherwise stated)

Particulars	Period ended on July 31, 2025	For year ended on March 31, 2025	For year ended on March 31, 2024	For year ended on March 31, 2023
Total revenue from operations (Net)	1,950.39	4,913.24	3,555.57	3,544.88
Net Profit / (Loss) before tax and extraordinary items	371.97	826.91	717.33	219.02
Net Profit / (Loss) after tax and extraordinary items	287.16	610.51	486.70	187.53
Equity Share Capital	593.44	593.44	50.00	50.00
Reserves and Surplus	1,316.46	1,029.30	537.28	50.58
Net worth	1,909.90	1,622.75	587.28	100.58
Basic earnings per share (Rs.)	4.84	10.29	97.34	37.51
Diluted earnings per share (Rs.)	4.84	10.29	97.34	37.51
Return on net worth (%)	15.04%	37.62%	82.87%	186.45%
Net asset value per share (Rs.)	32.18	27.34	9.96	1.71

For further details, see “**Restated Financial Statements**” beginning on page 236 of the Red Herring Prospectus.

INTERNAL RISK FACTORS

The below mentioned risks are top 10 risk factors as per the Red Herring Prospectus:

1. Our manufacturing facility is concentrated in Sanand, Ahmedabad, Gujarat, exposing us to risks from economic, regulatory, political, and other regional changes, including natural disasters, which could negatively impact our business operations, financial performance, and overall condition.
2. As a pharmaceutical company, we operate in a highly regulated industry where our business relies on obtaining approvals from relevant regulatory and health authorities. Delays or failures in securing or renewing these essential approvals, registrations, or changes in the regulatory environment for marketing our products in regulated markets could have a significant impact on our business and strategy, ultimately affecting our overall profitability.
3. Our business operations are subject to fluctuations in raw material prices.
4. Any non-compliance or delays in Instalments of Outstanding loan may expose us to penalties from the Bank.
5. The company relies on a limited number of customers for its sales, and the loss of any major customer could adversely impact our revenue and profitability.
6. The company relies on a limited number of suppliers for product procurement, and the loss of any key supplier could impact our business operations.
7. We depend on a limited number of States for a significant portion of our revenue from operations. The loss of any of our major customer in these States due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.
8. Our Company is dependent on few countries. Loss of any of these large countries may affect our business operations.
9. A disclosure remark on compliance of Companies (Auditor’s Report) Order, 2020 towards non payment of statutory dues in financial year ended March 31, 2020, March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024 have been noted by our Statutory Auditors in their reports.
10. Our Company depends on some of our Products which contributes more than 90% of the total revenue of the company. The loss of any of this major Products due to any adverse development or significant reduction in business from our major customer may adversely affect our business, financial condition, results of operations and future prospects.

For further details on Risk Factors please see chapter titled “**Risk Factors**” beginning on page 25 of the Red Herring Prospectus.

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

A. Total number of outstanding litigations against the company and amount involved

Name	By/Against	Civil Proceedings	Criminal Proceedings	Tax Proceedings	Actions by Other Regulatory Authorities	Amount Involved (₹ in Lakhs)
Company	By	Nil	Nil	Nil	Nil	Nil
	Against	Yes	Yes	Nil	Nil	20.52
Promoter	By	Nil	Nil	Nil	Nil	Nil
	Against	Nil	Yes	Nil	Nil	Nil
Group Companies / Entities	By	Nil	Nil	Nil	Nil	Nil
	Against	Nil	Nil	Nil	Nil	Nil
Directors other than promoters	By	Nil	Nil	Nil	Nil	Nil
	Against	Nil	Yes	Nil	Nil	Nil
KMP and SMP	By	Nil	Nil	Nil	Nil	Nil
	Against	Nil	Nil	Nil	Nil	Nil
Total	-	-	-	-	-	20.52

For further details, see chapter titled “*Outstanding Litigations & Material Developments*” beginning on page 284 of the Red Herring Prospectus.

B. Brief details of top 5 material outstanding litigations against the company and amount involved

Except as mentioned below there are no outstanding litigations initiated against our Company, which have been considered material by the Company in accordance with the Materiality Policy as on the date of this Red Herring Prospectus:

Sr No.	Details
1	<p>M/s. Curis Life Sciences Private Limited vs. Regional Provident Fund Commissioner-II & Anr. – R/Special Civil Application No. 8283 of 2024</p> <p>M/s. Curis Life Sciences Private Limited (“Petitioner”) filed a Special Civil Application bearing No. 8283 of 2024 before the Hon’ble High Court of Gujarat under Article 226 of the Constitution of India against the Regional Provident Fund Commissioner-II and another (“Respondents”), challenging the initiation of recovery proceedings under Section 7A of the Employees’ Provident Funds and Miscellaneous Provisions Act, 1952.</p> <p>Curis Lifesciences Private Limited (the Company), received a notice from the office of the Employees’ Provident Fund Organisation (EPFO) for non-compliance with Sections 6, 6A, and 6C of the Employees’ Provident Funds and Miscellaneous Provisions Act, 1952, read with Paragraph 38 of the Employees’ Provident Fund Scheme, 1952, Paragraph 3(1) of the Employees’ Pension Scheme, 1995, and Paragraph 8(1) of the Employees’ Deposit Linked Insurance Scheme, 1976.</p> <p>As per the applicable provisions, the Company was required to deposit the employees’ and employer’s share of the Employees’ Provident Fund and Employees’ Pension Fund, along with the employer’s share of the Insurance Fund contribution and the applicable administrative charges to the respective funds, within 15 days from the close of each month. However, as per the department the Company failed to remit the provident fund and other related dues for the period from June 2018 to January 2022, amounting to ₹25,32,638/-.</p> <p>Subsequently, the Assessing Enforcement Officer (AEO) passed an order dated April 5, 2024, wherein it was observed that some of the employees were not eligible for membership under the Act as their wages exceeded ₹15,000/- per month and they were not previous members of the Fund. Accordingly, the total dues were revised and reduced to ₹20,52,049/-. However, the department’s calculation, which was the basis for the aforementioned, was unacceptable to the company. Consequently, the company challenged the order, as stated in the DRHP. The core of the dispute lies in the difference between the department’s and the company’s calculations. The Petitioner contended that although an appeal had been filed against the Section 7A order dated April 12, 2024, the application under Section 7(O) of the Act for waiver of pre-deposit remained pending due to the non-availability of the Presiding Officer at the Central Government Industrial Tribunal (CGIT), Ahmedabad. It was submitted that coercive recovery steps by the Respondents, in the interim, would cause undue hardship.</p> <p>The Respondents, through counsel, argued that the charge of the CGIT, Ahmedabad, was temporarily held by the Jaipur Bench, which had not been extended, and emphasized that the Petitioner had not made the required deposit to claim relief. However, the Hon’ble High Court, relying on the precedent set in Special Civil Application No. 6511 of 2022, allowed the petition on the ground of non-availability of the Tribunal and granted protection against coercive steps.</p> <p>The Hon’ble Court directed that:</p> <ol style="list-style-type: none"> The Respondents shall not take any coercive steps against the Petitioner until the application under Section 7(O) is heard on merits by the Tribunal; The Court clarified it had not examined the matter on merits and disposed of the petition solely due to the unavailability of the Tribunal; The interim relief will remain in operation until the Tribunal considers the said application.

C. Regulatory Action, if any – disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any – Nil

D. Brief details of outstanding criminals proceedings against Promoters

1. Criminal Proceedings

As on the date of this Red Herring Prospectus, there are no outstanding criminal proceedings against our Promoters, except the following:

Sr No.	Details
--------	---------

1	<p>Drugs Inspector, Office of the Drugs Inspector, Kottayam vs. Curis Lifesciences Private Limited & Ors. – Criminal Misc. Petition No. 301851/2025</p> <p>The Drugs Inspector, Kottayam (“Complainant”), filed a Criminal Miscellaneous Petition bearing No. 301851/2025 before the Hon’ble Court of the Judicial First Class Magistrate – I, Pala, under Sections 18(a)(i) and 27(d) of the Drugs and Cosmetics Act, 1940, against Curis Lifesciences Private Limited and its Promoters (Mr. Dharmesh Dasharathbhai Patel, Mr. Siddhant Jayantibhai Pawasia, Mr. Piyush Gordhanbhai Antala, and Mr. Jaimik Mansukhbhai Patel) and Ors. (collectively referred to as “Respondents”).</p> <p>The complaint pertains to alleged contravention under the said provisions of the Act concerning the manufacture or sale of drugs that are not of standard quality or otherwise in violation of the law. The case was registered on May 16, 2025, and the Hon’ble Court held the first hearing on June 16, 2025, during which it directed that summons be issued to all the Respondents.</p> <p>However, as of date, none of the Respondent have received a copy of the summons, and the matter remains at a preliminary stage and the next date of hearing is scheduled on March 9, 2026.</p>
2	<p>Meridian Biotech Private Limited vs. Niral Mansukhbhai Patel & Ors. – Warrant or Summons Criminal Case No. 55105 of 2025.</p> <p>Meridian Biotech Private Limited (“Plaintiff”) has instituted a criminal complaint bearing Warrant or Summons Criminal Case No. 55105 of 2025 (“Complaint”) before the Hon’ble Court of Gautam Budh Nagar, Uttar Pradesh, against (i) Niral Mansukhbhai Patel; (ii) Kalpesh Prakashchandra Jain; (iii) Dilip Kumar Keshavlal Patel; (iv) Mauli Niral Patel; (v) Siddhant Jayantibhai Pawasia; (vi) Piyush Gordhanbhai Antala; (vii) Jaimik Mansukhlal Patel; (viii) Dharmesh Dasharathbhai Patel; (ix) Dhruvi Shyam Kapadia; (x) Chand Rameshbhai Kanabar; and (xi) Grishma A. Shewale (collectively referred to as the “Accused”).</p> <p>The Plaintiff, engaged in the manufacture and export of various pharmaceutical products, including its medicine CINEPAR, for which it holds a valid trade license and a registered trademark, has alleged that M/s. Medwise Overseas Private Limited exported a consignment of medicine to Tajikistan under the brand name CENIPAR, which is deceptively similar to the Plaintiff’s registered trademark CINEPAR. The said product was manufactured for M/s. Medwise Overseas Private Limited by M/s. Curis Lifesciences Private Limited on a contract manufacturing basis. The Plaintiff has further alleged that the manufacturers used an incorrect and unauthorized neutral code during the manufacturing process.</p> <p>The Complaint alleges violations under Section 210(1)(a) of the Bharatiya Nagarik Suraksha Sanhita. The matter is currently at a pre-cognizance stage, and the next date of hearing is scheduled for October 30, 2025.</p>

ANY OTHER IMPORTANT INFORMATION AS PER BRLM / ISSUER COMPANY - NIL

DECLARATION BY THE COMPANY

We hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India, and the regulations or guidelines issued by Securities and Exchange Board of India, established under Section 3 of the Securities and Exchange Board of India Act, 1992 as the case may be, have been complied with and no statement made in this Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, and the Securities and Exchange Board of India Act, 1992, each as amended or the rules, regulations or guidelines issued thereunder, as the case may be. We further certify that all the disclosures and statements made in this Red Herring Prospectus are true and correct.